XIENCE for Reduced DAPT

Dual antiplatelet therapy (DAPT) duration often depends on the patient—and it may depend on the stent as well.

Notably, the XIENCE everolimus-eluting stent (EES) has been associated with the lowest rates of early, late and very late stent thrombosis (ST).4-7 Therefore researchers have examined safety with a shortened DAPT following XIENCE implantation.8

STOPDAPT Study: XIENCE Safety Shown with 3-Month DAPT

STOPDAPT was the first prospective trial to study DAPT cessation at 3 months after EES implantation.

STOPDAPT Study Demonstrates 
XIENCE's Safety with 3-Month DAPT

1-Year XIENCE Event Rates Using 
3-Month DAPT



“Stopping DAPT at 3 months in selected patients after [XIENCE] implantation was at least as safe as the prolonged DAPT regimen adopted in the historical control group.” 

— Masahiro Natsuaki, MD, STOPDAPT Trial8

Expert's Point of View: Misperceptions About DAPT

"Long-term bleeding risks are actually increasing over time. . . . Every month that we prolong DAPT, that means that the patient has to pay a price."

Marco Valgimigli, MD

Play video

“It was noteworthy that no definite or probable stent thrombosis occurred in [XIENCE] patients enrolled in STOPDAPT.” 

— Masahiro Natsuaki, MD, STOPDAPT Trial8

DAPT Interruption

DAPT Interruption After 1 Month9


Timing of First DAPT Interruption and ST
Through 1 Year

Safety When DAPT Discontinued After 3 Months11

A study recently examined ST and DAPT use through 2 years in a large pooled sample of patients from the XIENCE family of clinical studies.11 The study revealed that discontinuing DAPT after 3 months appeared safe.


Definite/Probable Stent 
Thrombosis Rates

No Permanent Discontinuation
Through 2 Years


The majority (80%) of STs occurred while patients were on DAPT, and most (70%) of those patients had never discontinued DAPT for even a day prior to the ST event. Thus variables other than DAPT interruption—such as risk factors—could in fact be responsible for many of the ST events.11

Get the latest data

Sign up to receive the latest about XIENCE study results as they become available.

Sign up

† Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.

‡ Increased maximum expansion compared to other XIENCE Everolimus Eluting Coronary Stent System.

  1. Morice M-C, et al. JACC. 2013;61:1122-1123.
  2. Urban P, et al. Am Heart J. 2013;165:704-709. doi: 10.1016/j.ahj.2013.01.008.
  3. SPIRIT II (n = 223), SPIRIT III (n = 669), SPIRIT IV (n = 2,458), SPIRIT V (n = 1,662), SPIRIT Women (n = 1,506), XIENCE V USA (n = 6,516), XIENCE V India (n = 931), COMPARE (n = 897), STOPDAPT (n = 1,525).
  4. Baber U, et al. JACC. 2011;58:1569–1577. doi:10.1016/j.jacc.2011.06.049.
  5. Palmerini T, et al. Lancet. 2012;379:1393–1402. doi: 10.1016/S0140-6736(12)60324-9.
  6. Palmerini T, et al. Circ Cardiovasc Interv. 2012;5:357–364. doi: 10.1161/CIRCINTERVENTIONS.111.967083.
  7. Räber L, et al. Circulation. 2012;125:1110–1121. doi: 10.1161/CIRCULATIONAHA.111.058560.
  8. Natsuaki M, et al. STOPDAPT Trial. Cardiovasc Interv Ther. 2016;31:196–209.
  9. Généreux P. Everolimus Stent Family Trials. TCT 2012.
  10. Including patients with no DAPT interruption except possibly after stent thrombosis though 365 days. DAPT was considered to be interrupted if aspirin or a thienopyridine was not taken for at least 24 hours during the 2-year follow-up period for any reason. Patients who experience early discontinuation of antiplatelet therapy should be monitored carefully for cardiac events. At the discretion of the treating physician, the antiplatelet therapy should be restarted as soon as possible per patient needs. Ultimately the DAPT regimen is up to the discretion of the treating physician. This is a post-hoc, pooled analysis.  
  11. Généreux P, et al. Circ Cardiovasc Interv. 2015;8:e001362. doi:10.1161/CIRCINTERVENTIONS.114.001362. 

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?


The website you have requested is a product-specific website that is NOT intended for U.S. residents. This web content is exclusively reserved for health care professionals in countries with applicable health authority product registrations.

If you are a resident of a country other than those to which the site is directed, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

Do you wish to continue to visit this website?